Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 4, 2007, Pages 475-482

  Ogata, Yutaka ^a   Mori, S ^a   Ishibashi, N ^a   Akagi, Y ^a   Ushijima, M ^a   Murakami, H ^a   Fukushima, T ^a   Shirouzu, K ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal carcinoma; Irinotecan; Metronomic chemotherapy; Postoperative adjuvant chemotherapy; UFT

Indexed keywords

IRINOTECAN; UFT;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TEGAFUR; URACIL;

EID: 38549129734     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. International Multicentric Pooled Analysis of Colon Cancer Trials (IMPACT) investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939-944, 1995.
2. International Multicentric Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J. Clin. Oncol. 17: 1356-1363, 1999.
3. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., de Gramont A.: Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350:2343-2351, 2004.
4. Lembersky B.C., Wieand H.S., Petrelli N.J., O'Connell M.J., Colangelo L.H., Smith R.E., Seay T.E., Giguere J.K., Marshall M.E., Jacobs A.D., Colman L.K., Soran A., Yothers G., Wolmark N.: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J. Clin. Oncol. 24:2059-2064, 2006.
5. rd, Carrato A., Cassidy J., Cervantes A., Fagerberg J., Georgoulias V., Husseini F., Jodrell D., Koralewski P., Kroning H., Maroun J., Marschner N., McKendrick J., Pawlicki M., Rosso R., Schuller J., Seitz J.F., Stabuc B., Tujakowski J., Van Hazel G., Zaluski J., Scheithauer W.: Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352:2696-2704, 2005.
6. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J. Clin. Oncol. 22:484-492, 2004.
7. Ogata Y., Matono K., Sasatomi T., Ishibashi N., Ohkita A., Mizobe T., Ogo S., Ikeda S., Ozasa H., Shirouzu K.: The MMP-9 expression determined the efficacy ofpostoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother. Pharmacol. 57:577-583, 2006.
8. Japanese Research Society for Cancer of the Colon and Rectum: General rules for clinical and pathological studies on cancer of the colon, rectum and anus (6th edition). Kanehara & Co, Tokyo, Japan, 1998.
9. Shimada Y., Yoshino M., Wakui A., Nakao I., Futatsuki K., Sakata Y., Kambe M., Taguchi T., Ogawa N.: (CPT-11 Gastrointestinal Cancer Study Group): Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin.Oncol. 11:909-913, 1993.
10. Rothenberg M.L., Cox J.V., deVore R.F., Hainsworth J.D., Pazdur R., Rivkin S.E., Macdonald J.S., Geyer C.E. Jr, Sandbach J., Wolf D.L., Mohrland J.S., Elfring G.L., Miller L.L., Von Hoff D.D.: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85:786-795, 1999.
11. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., Elfring G.L., Miller L.L.: (Irinotecan Study Group): Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343:905-914, 2000.
12. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., Jemes R.D., Karasek P., Jandik P., Iveson T., Carmichael J., Arakl M., Gruia G., Awad L., Rougier P.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047, 2000.
13. Ychou M., Raoul J., Douillard J., Bugat R., Mineur L., Viret F., Becouarn Y., Bouche O., Jacob J., Gourgou-Bourgade S. for the GI Group of the FNCLCC and the FFCD: A phase III randomized trial of LV5FU2+CPT-11 vs LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord 02/FFCD 9802). J. Clin. Oncol. 23: (Suppl) abstract 3502, 2005.
14. Van Cutsem E, Labianca R, Hossfeld D, Bodoky G, Roth A, Aranda E, Nordlinger B, Assadourian S, Wang K, Cunningham D (PETACC 3): Randomized phase III trial comparing infused irinotecan / 5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients. J. Clin. Oncol. 23: (Suppl) abstract 8, 2005.
15. Miller K.D., Sweeney C.J., Sledge G.W. Jr.: Redefining the target: chemotherapeutics asantiangiogenics: J. Clin. Oncol. 19:1195-1206, 2001.
16. Kerbel R.S. and Kamen B.A.: The antiangiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4:423-436, 2004.
17. Takahashi Y., Mai M.: Antibody against vascular endothelial growth factor (VEGF) inhibits angiogenic switch and liver metastasis in orthotopic xenograft model with site-dependent expression of VEGF. J. Exp. Clin. Cancer Res. 24:237-243, 2005.
18. Guichard S., Hennebelle I., Bugat R., Canal P.: Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem. Pharmacol. 55:667-676, 1998.
19. Sadahiro S., Ohki S., Yamaguchi S., Takahashi T., Otani Y., Tsukikawa S., Yamamura T., Takemiya S., Nagasaki H., Nishiyama K., Fukushima T., Hiki Y., Yamaguchi S., Kumada K., Shimada H., Mitomi T., Makuuchi H.: Feasibility of a novel weekday-on/weekend-off oral UFT schedule aspostoperative adjuvant chemotherapy for colorectal cancer. Cancer Chemother. Pharmacol. 46:180-184, 2000.
20. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., Bonetti A.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2938-2947, 2000.
21. Scheithauer W., McKendrick J., Begbie S., Borner M., Burns W.I., Burris H.A., Cassidy J., Jodrell D., Koralewski P., Levine E.L., Marschner N., Maroun J., Garcia-Alfonso P., Tujakowski J., Van Hazel G., Wong A., Zaluski J., Twelves C.; X-ACT Study Group: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann. Oncol. 14:1735-1743, 2003.
22. Folkman J: What is the evidence that tumors are angiogencsis dependent? J. Natl. Cancer Inst. 84:4-6, 1990.
23. Yonekura K., Basaki Y., Chikahisa L., Okabe S., Hashimoto A., Miyadera K., Wierzba K., Yamada Y.: UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin. Cancer Res. 5:2185-2191, 1999.
24. Alonso V., Escudero P., Zorrilla M., Isla M.D., Herrero A., Mayordomo J.I., Martinez-Trufero J., Saenz A., Tres A., Anton A.: Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. Eur. J. Cancer 37:2385-2391, 2001.
25. Mendez M., Alfonso P.G., Pujol E., Gonzalez E., Castanon C., Cerezuela P., Lopez-Mateos Y., Cruz J.J.: Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. Invest. New. Drugs. 23:243-251, 2005.
26. Alonso V., Escudero P., Grandez R., Alvarez I., de Lobera R.A., Polo E., Corral M., Lara R., Puertolas T., Anton A.: Weekly irinotecan (CPT-11) combined with uracil-tegafur (UFT) as first line treatment for metastatic colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. 22 abstract 1344, 2003.
27. Duda D.G., Cohen K.S., di Tomaso E., Au P., Klein R.J., Scadden D.T., Willett C.G., Jain R.K.: Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers forantiangiogenic therapy. J. Clin. Oncol. 24:1449-1453, 2006.
28. Shaked Y., Emmenegger U., Man S., Cervi D., Bertolini F., Ben-David Y., Kerbel R.S.: Optimal biologic dose of metronomic chemotherapy regimens is associated with maximumantiangiogenic activity. Blood 106:3058-3061, 2005.
29. Ogata Y., Sasatomi T., Mori S., Matono K., Ishibashi N., Akagi Y., Fukushima T., Murakami H., Ushijima M., Shirouzu K.: Significance of Thymidine Phosphorylase in Metronomic Chemotherapy using CPT-11 and Doxifluridine for Advanced Colorectal Carcinoma. Anticancer Res. 27: 2605-2612, 2007.
30. Japanese Society for Cancer of the Colon and Rectum: Multiinstitutional Registry of Large Bowel Cancer in Japan, Cases treated in 1995. (Vol. 25), Tokyo, 2005.
31. Iwasaki A., Shirakusa T., Yamashita Y., Noritomi T., Maekawa T., Hamada T.: Characteristic differences between patients who have undergone surgical treatment for lung metastasis or hepatic metastasis from colorectal cancer. Thorac. Cardiovasc. Surg. 53:358-364, 2005.